You are about to leave the Clinical Value website now.


Debate: All resectable stage II to III NSCLC patients should be treated with neoadjuvant immunotherapies

Prof Enriqueta Felip

Head of the Thoracic and Head and Neck Cancer Unit, Oncology Department of Vall d’Hebron Hospital, Barcelona, Spain

Prof Haiquan Chen

Chairman, Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, China


Be the first to receive updates, event opportunities, and thought leadership insights.